Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Protalix BioTherapeutics Q3 2026 Results: Net Income $3.96M, Up 68.2% YoY

Protalix BioTherapeutics reported a significant turnaround for the nine months ended September 30, 2026, with net income of $26.1 million compared to a net loss of $1.1 million in the prior year period. This growth was driven by a substantial increase in total revenue to $75.6 million, primarily due to a surge in license and R&D services revenue.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue21.917.9
Profit before tax4.62.2
Net income4.02.4
EPS (diluted, $ a share)$0.05$0.03

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year+68.2%
Revenue, year on year+22.8%
Operating margin18.5%
Source

10-Q filed with the SEC, NYSE: PLX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Protalix BioTherapeutics, Inc.: key numbers

Share price
$3.03Close, Nov 16
Market cap
$255M
Shares outstanding
84.32MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Protalix BioTherapeutics, Inc.

All →
6:54 AM ET 8-K
Financial Results

Protalix BioTherapeutics Financial Results

Protalix BioTherapeutics reported Q3 2026 financial results with total year-to-date revenues reaching $75.6 million, a significant increase from $43.6 million in the prior year. The company reported quarterly net income of $4.0 million and reaffirmed its full-year 2026 revenue guidance of $78.0 million to $83.0 million. Management highlighted the ongoing Phase 2 RELEASE study for PRX-115 in uncontrolled gout, with top-line results expected in the second half of 2027.

Term
Q3 2026

“We concluded the first nine months of 2026 with revenues of $75.6 million, reflecting our continued progress and growing financial strength which supports our ability to execute our strategy and advance our key priorities.”

Dror Bashan, President and Chief Executive Officer

“We end the quarter with cash and deposits of $48.5 million, a position of strength that enables us to continue advancing PRX-115 for uncontrolled gout. Uncontrolled gout is a disease with low quality of life and high unmet need and represents a blockbuster uricase market opportunity.”

Dror Bashan, President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.